痴呆症患者的高风险药物:一项随机临床试验
Sonal Singh1, Xiaojuan Li2, Noelle M Cocoros2
1Department of Family Medicine and Community Health, Division of Health Systems Science, UMass Chan Medical School, Worcester, Massachusetts.
向阿尔茨海默病患者及其临床医生发送的教育邮件并没有减少高风险药物使用. 这项研究发现,干预和常规护理组之间的抑郁率没有显著差异.
科学领域:
- 老年学是一门学科.
- 临床药房 临床药房
- 神经学 神经学
背景情况:
- 患有阿尔茨海默氏症 (AD) 和阿尔茨海默氏症相关痴呆症 (ADRD) 的人有较高风险药物不良后果的风险.
- 在这种人群中,可能不适当的抗精神病药物,镇静催眠药和强抗胆药的处方是令人担忧的.
研究的目的:
- 评估邮寄教育干预对患者/护理人员和处方医生的有效性,以减少潜在的不适当处方对患有AD或ADRD的患者.
主要方法:
- 一个前性的,开放的,务实的随机临床试验,涉及使用向高风险药物治疗ADRD/ADRD患者.
- 参与者被随机分配到三个组:患者/处方者邮件,仅处方者邮件或通常护理.
- 主要结局是在6个月的时间内分发向药物.
主要成果:
- 该研究包括12,787名患者;68.4%是女性,平均年龄为77.3岁.
- 发放向药物的累积发病率在各组中相似:76.7% (患者/处方者),77.9% (仅处方者) 和77.5% (常规护理).
- 危险比率在干预组和通常护理之间在药物发行方面没有显著差异.
结论:
- 向患有AD/ADRD的患者及其临床医生发送的药物特定教育邮件在减少使用高风险药物的过程中并不有效.
- 干预没有导致显著的减缓处方或改变药物剂量或医疗服务使用情况.
更多相关视频
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
相关概念视频
Alzheimer's Disease: Treatment
Drug Therapy
Antianxiety Medications
Dementia
The progression of dementia is generally gradual....
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
